SOAM
XENE icon

SBI Okasan Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

SBI Okasan Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$866K Hold
14,400
– – 0.03% 148
2026
Q1 		$800K Hold
14,400
– – 0.03% 136
2025
Q4 		$638K Buy
+14,400
New +$605K 0.04% 170

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SBI Okasan Asset Management's XENE Position: Q2 2026 in Review

SBI Okasan Asset Management held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 14,400 shares worth $866K. The position accounts for 0.03% of the portfolio, ranked #148.

SBI Okasan Asset Management first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • SBI Okasan Asset Management held 14,400 shares of Xenon Pharmaceuticals worth $866K as of Q2 2026.
  • SBI Okasan Asset Management left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up 0.03% of SBI Okasan Asset Management's portfolio in Q2 2026, its #148 holding.
  • SBI Okasan Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.